Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitor – Endpoints News

Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitor  Endpoints NewsLilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera  Eli LillyLilly pens $2.3B deal for next-gen JAK inhibitor biotech Ajax  Fierce BiotechLilly to buy startup Ajax in bid for a better JAK drug  BioPharma DiveEli Lilly’s Ajax Deal Recasts Growth Story Beyond GLP 1 Strength  simplywall.st